Downloads and Tools

•  Article PDF
  817.81 KB PDF document

This is an open access article.
Print this page Email this page

Recipient's Email:

---

Article Citation

RIS
MARC (XML)
FULL CITATION (TXT)

---

Share on Facebook

Authors: Ping-Pin Zheng, Marcel van der Weiden, Peter J. van der Spek, Arnaud J.P.E. Vincent and Johan M. Kros

Ping-Pin Zheng

Corresponding author: p.zheng.1@erasmusmc.nl
Department of Pathology; Erasmus Medical Center; Rotterdam, The Netherlands

Marcel van der Weiden

Department of Pathology; Erasmus Medical Center; Rotterdam, The Netherlands

Peter J. van der Spek

Department of Bioinformatics; Erasmus Medical Center; Rotterdam, The Netherlands

Arnaud J.P.E. Vincent

Department of Neurosurgery; Erasmus Medical Center; Rotterdam, The Netherlands

Johan M. Kros

Corresponding author: j.m.kros@erasmusmc.nl
Department of Pathology; Erasmus Medical Center; Rotterdam, The Netherlands

Abstract:
Somatic mutation of Isocitrate dehydrogenase 1 (IDH1) at the locus of R132 (IDH1^R132H) occurs in > 70% of WHO grade II-III gliomas and secondary glioblastomas. To date it remains unknown whether the mutation is restricted to glial tumor cells. Microglial cells are the resident macrophages in the central nervous system. Tumor-infiltrating microglial cells/macrophages are major stromal cellular components of malignant gliomas and substantially contribute to the tumor mass. Differential identification of the IDH1^R132H mutant cellular components is of particular importance for understanding of the mutation-associated tumor biology. Here we discovered that a significant portion of CD68⁺, Iba1⁺, CX3CR1⁺ microglial cells/macrophages also harbor the IDH1R132H mutation. The findings provide novel insights for understanding the mutation-associated tumor biology relevant to clinical applications as a predictive and/or prognostic marker or therapeutic target.

Received: May 15, 2012; Accepted: May 22, 2012

Preview: